Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein i antibodies in patients with endstage renal disease

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Serrano, Manuel ^a   Martínez Flores, Jose Angel ^a   Castro, Maria José ^a   García, Florencio ^a   Lora, David ^a   Pérez, Dolores ^a   Gonzalez, Esther ^a   Paz Artal, Estela ^a,b,c   Morales, Jose M ^a,c   Serrano, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CREATININE; IMMUNOGLOBULIN A ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; ANTI-IGA; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD DONOR; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD; FEMALE; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATHOLOGY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIPHOSPHOLIPID SYNDROME; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84900335874     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/641962     Document Type: Article

References (57)

1. Leskinen Y., Lehtimäki T., Loimaala A., Lautamatti V., Kallio T., Huhtala H., Salenius J. P., Saha H., Carotid atherosclerosis in chronic renal failure-the central role of increased plaque burden. Atherosclerosis 2003 171 2 295 302 2-s2.0-0344464806 10.1016/j.atherosclerosis.2003.08.010 (Pubitemid 37486082)
2. Kovacic V., Ljutic D., Dodig J., Radic M., Duplancic D., Influence of haemodialysis on early markers of atherosclerosis. Nephrology 2008 13 6 472 479 2-s2.0-52649141482 10.1111/j.1440-1797.2008.00945.x
3. Foley R. N., Parfrey P. S., Sarnak M. J., Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology 1998 9 12 S16 S23 2-s2.0-0032229826
4. Sarnak M. J., Cardiovascular complications in chronic kidney disease. American Journal of Kidney Diseases 2003 41 6 S11 S17 2-s2.0-0037762928 (Pubitemid 36637964)
5. Pilmore H., Dent H., Chang S., McDonald S. P., Chadban S. J., Reduction in cardiovascular death after kidney transplantation. Transplantation 2010 89 7 851 857 2-s2.0-77950944041 10.1097/TP.0b013e3181caeead
6. Berthoux F., Mariat C., Cardiovascular death after renal transplantation remains the first cause despite significant quantitative and qualitative changes. Transplantation 2010 89 7 806 2-s2.0-77950925311 10.1097/TP. 0b013e3181caeece
7. Triplett D. A., Antiphospholipid antibodies. Archives of Pathology and Laboratory Medicine 2002 126 11 1424 1429 2-s2.0-0036881080 (Pubitemid 36237295)
8. de Groot P. G., Urbanus R. T., The significance of autoantibodies against beta2-glycoprotein I. Blood 2012 120 2 266 274
9. Pierangeli S. S., Chen P. P., Raschi E., Scurati S., Grossi C., Borghi M. O., Palomo I., Harris E. N., Meroni P. L., Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms. Seminars in Thrombosis and Hemostasis 2008 34 3 236 250 2-s2.0-50249189294 10.1055/s-0028-1082267
10. Moestrup S. K., Schousboe I., Jacobsen C., Leheste J.-R., Christensen E. I., Willnow T. E., β 2-glycoprotein-I (apolipoprotein H) and β 2-glycoprotein-I- phospholipid complex harbor a recognition site for the endocytic receptor megalin. Journal of Clinical Investigation 1998 102 5 902 909 2-s2.0-0032148360 (Pubitemid 28419235)
11. Klærke D. A., Røjkjær R., Christensen L., Schousboe I., Identification of β 2-glycoprotein I as a membrane-associated protein in kidney: Purification by calmodulin affinity chromatography. Biochimica et Biophysica Acta 1997 1339 2 203 216 2-s2.0-0031584226 10.1016/S0167-4838(96) 00233-6 (Pubitemid 27220245)
12. Miyakis S., Lockshin M. D., Atsumi T., Branch D. W., Brey R. L., Cervera R., Derkesen R. H. W. M., De Groot P. G., Koike T., Meroni P. L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P. G., Krilis S. A., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006 4 2 295 306 2-s2.0-33344458573 10.1111/j.1538-7836.2006.01753.x
13. Murthy V., Willis R., Romay-Penabad Z., Value of isolated IgA anti-beta GPI positivity in the diagnosis of the antiphospholipid syndrome. Arthritis & Rheumatology 2013 65 12 3186 3193
14. Staub H. L., Franck M., Ranzolin A., Norman G. L., Iverson G. M., von Mühlen C. A., IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmunity Reviews 2006 6 2 104 106 2-s2.0-33751311790 10.1016/j.autrev.2006. 06.014 (Pubitemid 44810183)
15. Andreoli L., Fredi M., Nalli C., Clinical significance of IgA anticardiolipin and IgA anti-beta2glycoprotein I antibodies. Current Rheumatology Reports 2013 15 7, article 343
16. Martinez-Flores J. A., Serrano M., Alfaro J., Mora S., Paz-Artal E., Morales J. M., Serrano A., Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Analytical Chemistry 2013 85 24 12093 12098 10.1021/ac403194t
17. Uthman I., Khamashta M., Antiphospholipid syndrome and the kidneys. Seminars in Arthritis and Rheumatism 2006 35 6 360 367 2-s2.0-33744946274 10.1016/j.semarthrit.2006.01.001 (Pubitemid 43841893)
18. Gronhagen-Riska C., Teppo A.-M., Helantera A., Honkanen E., Julkunen H., Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. British Medical Journal 1990 300 6741 1696 1697 2-s2.0-0025368096 (Pubitemid 20202363)
19. Brunet P., Aillaud M.-F., San Marco M., Philip-Joet C., Dussol B., Bernard D., Juhan-Vague I., Berland Y., Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney International 1995 48 3 794 800 2-s2.0-0029093304
20. Matsuda J., Saitoh N., Gohchi K., Tsukamoto M., Nakamura K., Kinoshita T., β 2-Glycoprotein I -Dependent and -independent anticardiolipin antibody in patients with end-stage renal disease. Thrombosis Research 1993 72 2 109 117 2-s2.0-0027488836 10.1016/0049-3848(93)90212-7 (Pubitemid 23294786)
21. Garcia-Martin F., De Arriba G., Carrascosa T., Moldenhauer F., Martin-Escobar E., Val J., Saiz F., Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrology Dialysis Transplantation 1991 6 8 543 547 2-s2.0-0025882940
22. Haviv Y. S., Association of anticardiolipin antibodies with vascular injury: possible mechanisms. Postgraduate Medical Journal 2000 76 900 625 628 2-s2.0-0033791125 10.1136/pmj.76.900.625
23. Gharavi E. E., Chaimovich H., Cucurull E., Celli C. M., Tang H., Wilson W. A., Gharavi A. E., Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 1999 8 6 449 455 2-s2.0-0032847566 (Pubitemid 29423579)
24. Ozmen S., Danis R., Akin D., Batun S., Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure. Clinical Nephrology 2009 72 3 193 198 2-s2.0-70350164190 10.2379/CNX06218
25. Roozbeh J., Serati A.-R., Malekhoseini S.-A., Arteriovenous fistula thrombosis in patients on regular hemodialysis: a report of 171 patients. Archives of Iranian Medicine 2006 9 1 26 32 2-s2.0-31144473509 (Pubitemid 43125288)
26. Pons-Estel G. J., Cervera R., Renal involvement in antiphospholipid syndrome. Current Rheumatology Reports 2014 16 2, article 397
27. Serrano A., García F., Serrano M., Ramírez E., Alfaro F. J., Lora D., de la Cámara A. G., Paz-Artal E., Praga M., Morales J. M., IgA antibodies against β 2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney International 2012 81 1239 1244 2-s2.0-84857127180 10.1038/ki.2011.477
28. Hadhri S., Rejeb M. B., Belarbia A., Achour A., Skouri H., Hemodialysis duration, Human platelet antigen HPA-3 and IgA Isotype of anti-beta2glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients. Thrombosis Research 2013 131 5 e202 e209
29. Morales J. M., Marcén R., Andrés A., Molina M. G., Castillo D. D., Cabello M., Capdevila L., Campistol J. M., Oppenheimer F., Serón D., Vernet S. G., Lampreave I., Valdés F., Anaya F., Escuín F., Arias M., Pallardó L., Bustamante J., Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney International 2008 111 S94 S99 2-s2.0-61549139778
30. Majka D. S., Liu K., Pope R. M., Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflammation Research 2013 62 10 919 927
31. Blank M., Asherson R. A., Cervera R., Shoenfeld Y., Antiphospholipid syndrome infectious origin. Journal of Clinical Immunology 2004 24 1 12 23 2-s2.0-1642390876 10.1023/B:JOCI.0000018058.28764.ce (Pubitemid 38375790)
32. McIntyre J. A., Wagenknecht D. R., Faulk W. P., Antiphospholipid antibodies in heart transplant recipients. Clinical Cardiology 1995 18 10 575 580 2-s2.0-0029609825 (Pubitemid 26034656)
33. Furmanczyk-Zawiska A., Tronina O., Baczkowska T., Chmura A., Durlik M., The significance of antiphospholipid antibodies in liver recipients. Transplantation Proceedings 2013 45 5 1983 1989
34. Van Thiel D. H., George M., Brems J., Holt D., Zhu Q., Edelstein S., Amiral J., Tarasuk G., Leone N., Antiphospholipid antibodies before and after liver transplantation. American Journal of Gastroenterology 2003 98 2 460 465 2-s2.0-0037286095 10.1016/S0002-9270(02)05888-4 (Pubitemid 36232400)
35. Phelan P. J., O'Kelly P., Tarazi M., Tarazi N., Salehmohamed M. R., Little D. M., Magee C., Conlon P. J., Renal allograft loss in the first post-operative month: causes and consequences. Clinical Transplantation 2012 26 4 544 549 2-s2.0-84855800333 10.1111/j.1399-0012.2011.01581.x
36. Morales J. M., Marcen R., del Castillo D., Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrology Dialysis Transplantation 2012 27 supplement 4 iv39 iv46
37. Ghisdal L., Broeders N., Wissing K. M., Mena J. M., Lemy A., Wijns W., Pradier O., Donckier V., Racapé J., Vereerstraeten P., Abramowicz D., Thrombophilic factors in Stage v chronic kidney disease patients are largely corrected by renal transplantation. Nephrology Dialysis Transplantation 2011 26 8 2700 2705 2-s2.0-79961059922 10.1093/ndt/gfq791
38. Rowley M. J., Mackay I. R., McKenzie I. F., Antibody production in immunosuppressed recipients of renal allografts. The Lancet 1969 2 7623 708 710 2-s2.0-0014663865
39. Heidt S., Roelen D. L., Eijsink C., Eikmans M., Van Kooten C., Claas F. H. J., Mulder A., Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clinical and Experimental Immunology 2010 159 2 199 207 2-s2.0-72949113433 10.1111/j.1365-2249.2009.04051.x
40. Morell A., Skvaril F., Noseda G., Barandun S., Metabolic properties of human IgA subclasses. Clinical and Experimental Immunology 1973 13 4 521 528 2-s2.0-0015609060
41. Keeling D., Mackie I., Moore G. W., Greer I. A., Greaves M., Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology 2012 157 1 47 58 2-s2.0-84858283382 10.1111/j.1365-2141. 2012.09037.x
42. Derksen R. H. W. M., De Groot P. G., Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010 19 4 470 474 2-s2.0-77951230873 10.1177/0961203309361483
43. Broder A., Putterman C., Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. The Journal of Rheumatology 2013 40 1 30 33
44. Tripodi A., de Groot P. G., Pengo V., Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine 2011 270 2 110 122 2-s2.0-79959382588 10.1111/j.1365-2796.2011.02362.x
45. Fonseca A. G., D'Cruz D. P., Controversies in the antiphospholipid syndrome: can we ever stop warfarin? Journal of Autoimmune Diseases 2008 5, article 6 2-s2.0-60149101072 10.1186/1740-2557-5-6
46. Pengo V., APS-controversies in diagnosis and management, critical overview of current guidelines. Thrombosis Research 2011 127 3 S51 S52 2-s2.0-79251516400 10.1016/S0049-3848(11)70014-7
47. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., De Micheli V., Gresele P., Tonello M., Ghirarduzzi A., Bison E., Denas G., Banzato A., Jose S. P., Iliceto S., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A Multicenter Prospective Study. Blood 2011 118 17 4714 4718 2-s2.0-80055066032 10.1182/blood-2011-03-340232
48. Ruffatti A., Del Ross T., Ciprian M., Bertero M. T., Sciascia S., Scarpato S., Montecucco C., Rossi S., Caramaschi P., Biasi D., Doria A., Rampudda M., Nuzzo M., Fischetti F., Picillo U., Brucato A., Salvan E., Pengo V., Meroni P., Angela Tincani A. T., Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases 2011 70 6 1083 1086 2-s2.0-79955815184 10.1136/ard.2010.142042
49. Ruffatti A., Del Ross T., Ciprian M., Nuzzo M., Rampudda M., Bertero M. T., Bergia R., Caramaschi P., Biasi D., Capsoni F., Montaguti L., Ruffini R., Brucato A., Picillo U., Fanelli V., Riccieri V., Piccoli A., Valesini G., Doria A., Meroni P. L., Tincani A., Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Annals of the Rheumatic Diseases 2009 68 3 397 399 2-s2.0-61449186513 10.1136/ard.2008.096669
50. Tsuruta D., Ishii N., Hashimoto T., Diagnosis and treatment of pemphigus. Immunotherapy 2012 4 7 735 745
51. Meurer M., Immunosuppressive therapy for autoimmune bullous diseases. Clinics in Dermatology 2012 30 1 78 83 2-s2.0-83155160946 10.1016/j. clindermatol.2011.03.013
52. Sanders D. B., Evoli A., Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010 43 5-6 428 435 2-s2.0-77955888510 10.3109/ 08916930903518107
53. Cartin-Ceba R., Peikert T., Ashrani A., Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care & Research (Hoboken) 2014 66 2 301 310
54. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Baldovino S., Menegatti E., La Grotta R., Modena V., Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrology Dialysis Transplantation 2011 26 12 3987 3992 2-s2.0-80051863465 10.1093/ndt/gfr109
55. Rubenstein E., Arkfeld D. G., Metyas S., Shinada S., Ehresmann S., Liebman H. A., Rituximab treatment for resistant antiphospholipid syndrome. Journal of Rheumatology 2006 33 2 355 357 2-s2.0-32144435725 (Pubitemid 43209314)
56. Berman H., Rodriguez-Pinto I., Cervera R., Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmunity Reviews 2013 12 11 1085 1090
57. Kumar D., Roubey R. A. S., Use of rituximab in the antiphospholipid syndrome. Current Rheumatology Reports 2010 12 1 40 44 2-s2.0-77249103016 10.1007/s11926-009-0074-5